When was Mirxes founded?

Mirxes was founded in 2014 and raised its 1st funding round 2 years after it was founded.

Where is Mirxes located?

Mirxes is headquartered in Singapore, Singapore. It is registered at TUKANG INNOVATION GROVE, Singapore, 618305.

Who is the current CEO of Mirxes?

Zhou Lihan of Mirxes. They have also founded 1 company.

How many employees does Mirxes have?

As of Sep 30, 2026, the latest employee count at Mirxes is 165.

Is Mirxes a funded company?

Mirxes is a funded company, having raised a total of $254M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 05, 2016.

When was the latest funding round of Mirxes?

Mirxes' latest funding was a $***** Series D round on Jul 26, 2023, with participation from 3 investors.

What is the annual revenue of Mirxes?

Annual revenue of Mirxes is between SGD 10M and SGD 50M as on Dec 31, 2022

Where does Mirxes rank among its competitors?

Mirxes ranks 1st amongst 5 active competitors, of which 3 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Liquid Mine, which secured an undisclosed amount in May, 2025.

Who are the top competitors of Mirxes?

Mirxes' top competitors include Liquid Mine, Ilico Genetics and Biohit Healthcare. Among them, Liquid Mine secured the most recent funding round in May, 2025.

Mirxes - 2026 Company Profile, Team, Funding, Competitors & Financials

Mirxes is a public company based in Singapore (Singapore), founded in 2014 by Zhou Lihan and Zou Ruiyang. It operates as a Developer of miRNA based test for the detection of cancer. Mirxes has raised $254M in funding from investors like Venturecraft, EDBI and Mitsui. The company has 5 active competitors, including 3 funded and 1 that has exited. Its top competitors include companies like Liquid Mine, Ilico Genetics and Biohit Healthcare.

Company Details

Developer of miRNA-based test for the detection of cancer. The company's core technology is a highly specific RT-PCR primer that imposes a conformational restriction on miRNA for efficient binding to mature, but not precursor miRNAs, coupled with optimized RT-PCR reagents. These primers confer high specificity, sensitivity, and enhanced signal-to-noise ratio in amplification reactions. The company manufactures miRNA detection and quantification kits for research and is developing miRNA-based liquid biopsy kits for gastric cancer, lung cancer, and breast cancer detection.

Website: www.mirxes.com/
Social
Email ID: *****@mirxes.com
Registered Address: TUKANG INNOVATION GROVE, Singapore, 618305

Key Metrics

Founded Year

2014

Location

Singapore, Singapore

Stage

Public

Total Funding

$254M in 5 rounds

Latest Funding Round

Series D, Jul 26, 2023, $*****

Investors

Venturecraft & 12 more

Ranked

1^st among 5 active competitors

Annual Revenue

SGD 10M - 50M as on Dec 31, 2022

Employee Count

165 as on Sep 30, 2026

Investment & Acquisitions

Med247

Similar Companies

Liquid Mine & 3 more

Exit Details

Public

View Mirxes' full profile

Mirxes is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MIRXES PTE. LTD. UEN: 201407328H , Singapore, Active	Mar 14, 2014	SGD 10M - 50M (As on Dec 31, 2022)	-

Mirxes got listed on May 23, 2025.

Click here to take a look at Mirxes's IPO in detail

Mirxes has raised a total funding of $254M over 5 rounds. Its first funding round was on Sep 05, 2016. Its latest funding round was a Series D round on Jul 26, 2023 for $*****. 3 investors participated in its latest round. Mirxes has 13 institutional investors.

Here is the list of recent funding rounds of Mirxes:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 26, 2023	3119471	Series D	9224949	4972225	2349457	5175974
Oct 26, 2021	4166629	Series C	9841737	2978097	3557678	Rock Springs Capital & 5 more
Jul 10, 2021	7776328	Series C	6947287	1993204	Rock Springs Capital & 2 more	Keytone Ventures & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Mirxes's funding rounds and investors

The founders of Mirxes are Zhou Lihan and Zou Ruiyang. Zhou Lihan is the CEO of Mirxes.

Here are the details of Mirxes' key team members:

Zhou Lihan: Co-Founder & CEO of Mirxes and founder of 1 other company. They serve on the boards of 2 companies.
Contact Info: 2 email addresses
Zou Ruiyang: Co-Founder & CTO of Mirxes. They serve on the boards of 2 companies.

Mirxes' Board of Directors

Mirxes's board has 4 active members. Zhou Lihan and Zou Ruiyang are part of team and Too Heng Phon and Ho Hou Chiat Isaac are independent board members.

Here is the list of Mirxes' board of directors:

Name	Type	Representing	Status	Duration
Zhou Lihan	Team	-	Current	12y 6m
zpjcehm	Team	-	Current	4y 1m
Too Heng Phon	Independent board member	-	Current	12y 6m
mpjcoxg	Independent board member	-	Current	7y 4m
plhxmmy	Independent board member	-	Past	4y 8m
egqtmcj	Independent board member	-	Past	4y 4m

View details of Mirxes's Founder profiles and Board Members

Mirxes' employee count trend

Mirxes has 165 employees as of Sep 26. Here is Mirxes's employee count trend over the years:

Uncover Mirxes' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Mirxes include Liquid Mine, Ilico Genetics and Biohit Healthcare. Here is the list of Top 10 competitors of Mirxes, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Mirxes 2014, Singapore (Singapore), Public	Developer of miRNA based test for the detection of cancer	$254M	Rock Springs Capital, CCB International & 11 others	58/100
2nd	Liquid Mine 2019, Shibuya (Japan), Series A	Developer of monitoring test system for early detection of leukemia recurrence	$768K	Incubate Fund, Astart & 3 others	34/100
3rd	Ilico Genetics 2020, Bethlehem (United States), Seed	Developer of diagostic test for detection of gastric cancer	$458K	-	27/100
4th	Biohit Healthcare 2013, Hefei (China), Unfunded	Developer of in-vitro diagnostic test kits for infectious disease and gastric functions	-	-	25/100
5th	Oncobiomix 2023, San Antonio (United States), Seed	Developer of microbiome analysis and diagnostic tools for disease detection	$500K	-	16/100